- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | Femasys: EPS erfüllt Schätzungen - Umsatz schlechter als erwartet | 1 | Investing.com Deutsch | ||
| Mo | Femasys GAAP EPS of -$0.16 | 1 | Seeking Alpha | ||
| Fr | FEMASYS INC - 10-Q, Quarterly Report | 4 | SEC Filings | ||
| Fr | Femasys Inc.: Femasys Announces Second Quarter Financial Results for 2025 | 119 | GlobeNewswire (Europe) | -- Continued Progress on Regulatory Approvals and Global Commercialization of Fertility Portfolio -- ATLANTA, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical... ► Artikel lesen | |
| 06.08. | Femasys secures first European order for FemBloc | 3 | Seeking Alpha | ||
| 06.08. | FEMASYS INC - 8-K, Current Report | 1 | SEC Filings | ||
| FEMASYS Aktie jetzt für 0€ handeln | |||||
| 06.08. | Femasys Inc.: Femasys Secures First European Order for FemBloc, Marking Strategic Milestone in Global Expansion | 121 | GlobeNewswire (Europe) | --Initiation of access to FemBloc, a revolutionary non-surgical permanent contraceptive, as global availability accelerates-- ATLANTA, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY)... ► Artikel lesen | |
| 18.07. | FEMASYS INC - 8-K, Current Report | 4 | SEC Filings | ||
| 03.07. | FEMASYS INC - 8-K, Current Report | 1 | SEC Filings | ||
| 26.06. | Femasys-Aktie steigt nach CE-Kennzeichnung für FemBloc zur dauerhaften Empfängnisverhütung | 2 | Investing.com Deutsch | ||
| 26.06. | Femasys stock rises as FemBloc gets CE Mark for permanent birth control | 1 | Investing.com | ||
| 25.06. | FEMASYS INC - 8-K, Current Report | - | SEC Filings | ||
| 25.06. | Femasys Inc.: Femasys Announces Historic Milestone with European Approval of FemBloc, the First Non-Surgical Permanent Birth Control | 235 | GlobeNewswire (Europe) | ATLANTA, June 25, 2025 (GLOBE NEWSWIRE) -- Femasys Inc., (Nasdaq: FEMY), a leading biomedical innovator addressing significant unmet needs in women's health worldwide, with a broad portfolio of disruptive... ► Artikel lesen | |
| 17.06. | Femasys appoints Kelley Nicholas as chief commercial officer | 1 | Investing.com | ||
| 17.06. | FEMASYS INC - 8-K, Current Report | 1 | SEC Filings | ||
| 11.06. | The Analyst Verdict: Femasys In The Eyes Of 6 Experts | 2 | Benzinga.com | ||
| 11.06. | Femasys Inc.: Femasys Announces Partnership with Carolinas Fertility Institute, One of America's Best Fertility Clinics, to Offer FemaSeed in its More than 8 Locations | 1 | GlobeNewswire (USA) | ||
| 02.06. | FEMASYS INC - 8-K, Current Report | - | SEC Filings | ||
| 30.05. | Femasys Announces $4.5 Mln Offering Through Public Sale And Private Placement Of Shares | 1 | RTTNews | ||
| 30.05. | Femasys announces pricing of underwritten public offering and concurrent private placement with gross proceeds of $4.5M | 2 | Seeking Alpha |
1 2 3 Weiter >>
53 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| INTUITIVE SURGICAL | 410,95 | +0,31 % | ISRG's Post-Earnings Slide: Margin Worries Overshadow Growth Story | ||
| UNITEDHEALTH | 226,70 | +1,16 % | 3 Aktien mit Potenzial? BYD, UnitedHealth, FedEx im Check | Die US-Börsen haben sichtlich von den besser als erwartet ausgefallenen Inflationsdaten profitiert. Samir Boyardan und Andreas Wolf von HeavytraderZ analysieren die Lage und werfen darüber hinaus einen... ► Artikel lesen | |
| THERMO FISHER | 412,30 | +0,79 % | Plattform-Strategien krempeln Biotech-Markt um: BioNxt, Thermo Fisher Scientific, Evotec | Bei Biotech gilt längst nicht mehr das Prinzip alles oder nichts. Statt nur ein Produkt im Angebot zu haben, setzt sich bei der Entwicklung der Wirkstoffe von morgen die Plattform-Ökonomie durch. Was... ► Artikel lesen | |
| ROKU | 72,64 | +0,57 % | Roku's Next Bet: Launching the Cheapest Ad-Free Streaming Service | ||
| ATOSSA THERAPEUTICS | 0,680 | +2,72 % | Atossa Therapeutics Inc: Atossa Therapeutics Announces Second Quarter 2025 Financial Results and Provides a Corporate Update | FDA Provides Positive Feedback, Clears Path for Atossa to File IND for (Z)-Endoxifen in Metastatic Breast Cancer; FDA Indicates No Additional Toxicity Studies Required
Strong... ► Artikel lesen | |
| EVOFEM BIOSCIENCES | - | - | Windtree Therapeutics: Windtree Advances Lower Cost Manufacturing of PHEXXI, Evofem's Hormone-Free, On-Demand Prescription Contraceptive Gel | Windtree rapidly advancing lower cost PHEXXI manufacturing under March 2025 sourcing agreement Contract inked with outside U.S manufacturer to cut PHEXXI manufacturing costs by over 50% by end of... ► Artikel lesen | |
| CENTENE | 22,495 | +0,45 % | Sarah London, youngest CEO in Fortune 500 with US$20.6mn salary: Sarah London leads Centene, becoming youngest ... | ||
| VERU | 0,298 | 0,00 % | XFRA ISIN CHANGE | Einstellung Aufnahme ISIN Name Einstellung mit Ablauf: ISIN Name Ab dem: AnmerkungenCA8959792018 Trilogy AI Corp. 08.08.2025 CA88909Q1090 Tokenwell Platforms Inc. 11.08.2025 Tausch 1:1US92536C1036 Veru... ► Artikel lesen | |
| QUIDELORTHO | 21,400 | 0,00 % | QuidelOrtho Stock Gains Following Q2 Earnings Beat, Margins Expand | ||
| TEMPEST THERAPEUTICS | 6,010 | -100,00 % | Tempest Therapeutics: Tempest Reports Second Quarter 2025 Financial Results and Provides Business Update | Received clearance to proceed with pivotal trial of amezalpat combination therapy for first-line hepatocellular carcinoma (HCC) in ChinaGranted orphan drug designation from the European Medicines... ► Artikel lesen | |
| NANO-X IMAGING | 4,465 | 0,00 % | Nano-X Imaging Non-GAAP EPS of -$0.17 misses by $0.02, revenue of $3.04M misses by $0.16M | ||
| FULGENT GENETICS | 18,000 | 0,00 % | Fulgent Genetics: UBS stuft Aktie auf 'Kaufen' hoch und verweist auf Wachstumspotenzial | ||
| LANTHEUS | 45,900 | -0,54 % | Pre-market Movers: Myriad Genetics, LifeMD, Evolus, Lantheus Holdings, Astera Labs | OTTAWA (dpa-AFX) - The following are some of the stocks making big moves in Wednesday's pre-market trading (as of 08.15 A.M. ET).In the Green Myriad Genetics, Inc. (MYGN) is up over 30% at $5.04.
Astera... ► Artikel lesen | |
| PERSPECTIVE THERAPEUTICS | 3,160 | -7,06 % | Perspective Therapeutics, Inc. - 10-Q, Quarterly Report | ||
| AMN HEALTHCARE SERVICES | 14,900 | +3,47 % | AMN Healthcare Services Inc: AMN Healthcare Announces Second Quarter 2025 Results | Quarterly revenue of $658 million and Adjusted EBITDA of $58.3 million; GAAP loss of ($3.02)/share and adjusted EPS of $0.30 DALLAS, Aug. 07, 2025 (GLOBE NEWSWIRE) -- AMN Healthcare Services, Inc.... ► Artikel lesen |
Das Unternehmen FEMASYS INC kann der Branche Gesundheitswesen zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 0,731 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu FEMASYS INC finden Sie auf Wallstreet Online.